▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1139 by analyst upside · 2026-09-27
CTNM
Contineum Therapeutics, Inc.
Healthcare · Market Cap $473M · P/E 0x
ANALYST PRICE TARGET
+76.3%
implied upside to consensus target
Current Price $12.56
Consensus Target $22.14
Bull Target $28.0
Bear Target $17.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
1
Sell
0
52-Week Low $8.6
52-Week High $17.79
YTD Return +10.3%
FUNDAMENTALS
Market Cap $473M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.72
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.6
52-Week High $17.79
Current Price $12.56
Bear Target $17.0
Bull Target $28.0
● Now $12.56 ● Target $22.14
TRADING DATA
Avg Volume 460K
YTD Return +10.3%
Analyst Count 7
Consensus Buy
Upside to Target +76.3%
Last Updated 2026-09-27

ANALYST SUMMARY

Contineum Therapeutics, Inc. (CTNM) is currently trading at $12.56 with a Wall Street consensus price target of $22.14, implying potential upside of 76.3% over the next 12 months. 7 analysts currently cover CTNM, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $28.0, while the most cautious has a target of $17.0.

CTNM operates in the Healthcare sector with a market capitalisation of $473M. The stock is up 10.3% year-to-date and is currently trading near the lower end of its 52-week range of $8.6 – $17.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CRMD +95.3%
CorMedix Inc.
$612M · P/E 3.6x · Strong Buy
TCMD +71.6%
Tactile Systems Technology, Inc.
$515M · P/E 20.9x · Buy
IRWD +47.7%
Ironwood Pharmaceuticals, Inc.
$682M · P/E 5.2x · Buy
KMDA +54.8%
Kamada Ltd.
$503M · P/E 22.9x · Buy
ASMB +119.7%
Assembly Biosciences, Inc.
$482M · P/E 19.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CTNM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jones Trading - Reiterated
Buy → Buy 2026-09-15 57% win rate (14 calls)
Baird - Reiterated
Outperform → Outperform 2026-09-15 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-07-31 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-05-14 Building track record
Baird - Reiterated
Outperform → Outperform 2026-03-06 Building track record
Morgan Stanley ↓ Downgrade
Overweight → Equal-Weight 2026-01-08 Building track record
Baird - Reiterated
Outperform → Outperform 2025-11-24 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2025-11-21 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
16/30
Consensus clarity
12/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →